Substances Modifying the Activity of Caspases
Authors:
T. Bartl; P. Žádníková; R. Jiříkovská; B. Maroušková; L. Beneš
Authors‘ workplace:
Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav chemických léčiv
Published in:
Čes. slov. Farm., 2008; 57, 29-34
Category:
Original Articles
Overview
Caspases are enzymes which play a key role in programmed cell death – apoptosis. Dysregulation of this process results in a series of disorders in which apoptosis is involved in pathogenesis. Diseases could be divided into two groups – diseases with pathological inhibition of apoptosis (cancer, some autoimmune disorders) and diseases with pathological induction of apoptosis (neurodegenerative disorders, AIDS). The paper lists the most significant activators and inhibitors of caspases as they control apoptosis and hence they are widely studied nowadays. The effects of stobadine, theophylline and adenine derivatives on the activity of caspase 1 was investigated with the use of spectrophotometry. The compounds under study showed an inhibitory effect on the enzyme tested; in one case the inhibitory effect exceeded 80%.
Key words:
caspases – apoptosis – derivatives of stobadine, theophylline, adenine
Sources
1. Russell, S. W., Rosenau, W., Lee, J. C.: Am. J. Pathol., 1972; 69, 103–118.
2. Bózner, A., Fízel, A., Kopáčová, L. et al.: Farmakologická propedeutika, 1. vyd. Bratislava, Osveta, 1984; 277, 278.
3. https://www.zdravcentra.cz, staženo 5. 1. 2007.
4. Rosypal, S.: Úvod do molekulární biologie, 1. vyd. Blansko, Grafex, 1999; 485–488.
5. http://www.fnplzen.cz/, staženo 11. 2. 2007.
6. Steller, H.: Science, 1995; 267, 1445–1449.
7. Jacobson, M. D., Weil, M., Raff, M. C.: Cell, 1997; 88, 347–354.
8. Cohen, J. J.: Immunol. Today, 1993; 14, 126–130.
9. Trauth, B. C., Keesey, J.: Cell death. In: Trauth, B. C. Boehringer Mannheim, 1998; 34–61.
10. Rudin, C. M., Thompson, C. B.: Annu. Rev. Med., 1997; 48, 267–281.
11. Riedl, S. J., Shi, Y.: Nat. Rev. Mol. Cell Biol., 2004; 5, 897–907.
12. Li, P., Nijhawan, D., Budihardjo, I. et al.: Cell, 1997; 91, 479–489.
13. Reed, J. C.: Am. J. Pathol., 2000; 157, 1415–1431.
14. Green, D. R., Kroemer, G.: J. Clin. Invest., 2005; 115, 2610–2617.
15. Varfolomeev, E. E., Ashkenazi, A.: Cell, 2004; 116, 491–497.
16. Chinnaiyan, A. M.: Neoplasia, 1999; 1, 5–15.
17. Yan, N., Shi, Y.: Annu. Rev. Cell Dev. Biol., 2005; 21, 35–56.
18. Philchenkov, A.: J. Cell Mol. Med., 2004; 8, 432–444.
19. Ho, P. K., Hawkins, C. J.: FEBS Lett., 2005; 272, 5436–5453.
20. Yuan, J. Y., Shaham, S., Ledoux, S. et al.: Cell, 1993; 75, 641–652.
21. Twomey, C., McCarthy, J. V.: J. Cell Mol. Med., 2005; 9, 345–359.
22. Fan, T. J., Han, L. H., Cong, R. S., Liang, J.: Acta Biochim. Biophys. Sinica, 2005; 37, 719–727.
23. Wolf, B. B., Green, D. R.: J. Biol. Chem., 1999; 274, 20049–20052.
24. Degterev, A., Boyce, M., Yuan, J. Y.: Oncogene, 2003; 22, 8543–8567.
25. Shi, Y.: Mol. Cells, 2002; 9, 459–470.
26. Fuentes-Prior, P., Salvesen, G. S.: Biochem. J., 2004; 384, 201–232.
27. Lavrik, I. N., Golks, A., Krammer, P. H.: J. Clin. Invest., 2005; 115, 2665–2672.
28. http://is.muni.cz/ staženo 9. 2. 2007.
29. Jin, Z. Y., El-Deiry, W. S.: Cancer Biol. Ther., 2005; 4, 139–163.
30. Thompson, C. B.: Science, 1995; 267, 1456–1462.
31. http://ustavpatologie.upol.cz, staženo 15. 2. 2007.
32. Chwajol, B.: Urologie pro praxi, 2001; 3, 119–121.
33. http://www.sukl.cz/, staženo 14. 2. 2007.
34. Hideshima, T., Chauhan, D., Podar, K. et al.: Semin. Oncol., 2001; 28, 607–612.
35. http://www.chem-online.org/generic-pharmaceutical, staženo 19. 2. 2007.
36. Oancea, M., Mani, A., Hussein, M. A., Almasan, A.: Int. J. Hematol., 2004; 80, 224–231.
37. Ückert, S., Hedlund, P., Andersson, K. E. et al.: Eur. Urol., 2006; 50, 1194–1207.
38. Klener, P.: Sanquis, 2004; 36, 14–16.
39. http://redpoll.pharmacy.ualberta.ca, staženo 14. 2. 2007.
40. Graczyk, P. P.: Restor. Neurol. Neurosci., 1999; 14, 1–23.
41. Bonuccelli, U., Del Dotto, P.: Neurology, 2006; 67, 30–38.
42. Loher, F., Bauer, C., Landauer, N. et al.: J. Pharmacol. Exp. Ther., 2004; 308, 583–590.
43. http://merops.sanger.ac.uk, staženo 27. 2. 2007.
44. Concha, N. O., Abdel-Meguid, S. S.: Current Med. Chem., 2002; 9, 713–726.
45. Beneš, L., Pronayová, N.: Pharmazie, 1994; 49, 69–70.
46. Návody firmy Calbiochem: Calbiochem User Protocol, No. 218783.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2008 Issue 1
Most read in this issue
- Signal pathways of cell proliferation and death as targets of potential chemotherapeutics
- Hemostatic effects of oxidized cellulose
- Substances Modifying the Activity of Caspases
- Antioxidant activity of tinctures prepared from hawthorn fruits and motherwort herb